STRS Ohio’s Acrivon Therapeutics ACRV Stock Holding History

STRS Ohio’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-800	Closed	-$1.62K	–	2196
2025 Q1	$1.62K	Hold	800	–	–	﹤0.01%	1914
2024 Q4	$4.82K	Hold	800	–	–	﹤0.01%	1865
2024 Q3	$5.6K	Hold	800	–	–	﹤0.01%	1949
2024 Q2	$4.64K	Hold	800	–	–	﹤0.01%	1937
2024 Q1	$5K	Hold	800	–	–	﹤0.01%	1894
2023 Q4	$3K	Hold	800	–	–	﹤0.01%	1893
2023 Q3	$7K	Hold	800	–	–	﹤0.01%	1911
2023 Q2	$10K	Sell	800 -1,000	-56%	-$12.1K	﹤0.01%	1910
2023 Q1	$22K	Buy	+1,800	New	+$30.2K	﹤0.01%	1860

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

STRS Ohio's ACRV Position: Q2 2025 in Review

STRS Ohio sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 800 shares — an estimated $1.62K sold.

STRS Ohio first reported a position in ACRV in Q1 2023 and held it in 9 quarters. The position peaked at $22K in Q1 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

STRS Ohio reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
STRS Ohio sold 800 Acrivon Therapeutics shares in Q2 2025, an estimated $1.62K.
STRS Ohio first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 9 quarters.
STRS Ohio's Acrivon Therapeutics position peaked at $22K in Q1 2023.
53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on STRS Ohio's 13F filing for Q2 2025, filed 4 Aug 2025.